1. Home
  2. EQX vs PRAX Comparison

EQX vs PRAX Comparison

Compare EQX & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Equinox Gold Corp.

EQX

Equinox Gold Corp.

HOLD

Current Price

$11.51

Market Cap

10.9B

ML Signal

HOLD

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$264.55

Market Cap

9.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EQX
PRAX
Founded
2007
2015
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.9B
9.0B
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
EQX
PRAX
Price
$11.51
$264.55
Analyst Decision
Buy
Strong Buy
Analyst Count
1
15
Target Price
$17.00
$572.13
AVG Volume (30 Days)
9.7M
378.0K
Earning Date
05-06-2026
05-08-2026
Dividend Yield
0.11%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$102.84
N/A
Revenue Next Year
$15.55
$7,758.26
P/E Ratio
$137.41
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.64
$37.25
52 Week High
$18.96
$366.52

Technical Indicators

Market Signals
Indicator
EQX
PRAX
Relative Strength Index (RSI) 37.04 33.30
Support Level $10.28 $157.29
Resistance Level $15.44 $342.62
Average True Range (ATR) 0.62 21.69
MACD -0.11 -9.38
Stochastic Oscillator 10.70 9.02

Price Performance

Historical Comparison
EQX
PRAX

About EQX Equinox Gold Corp.

Equinox Gold Corp is a mining company engaged in the operation, acquisition, exploration, and development of mineral properties, with a focus on gold. The company operates gold mines and a clear plan to increase production by advancing the pipeline of growth projects. Geographically, the company operates in the Canada, United States, Mexico, and others. The majority of its revenue is generated from Canada.

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

Share on Social Networks: